Shandong Weigao Group Medical Polymer
Market Cap
US$37.5b
Last Updated
2019/09/18 00:21 UTC
Data Sources
Company Financials +
Executive Summary
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China.
Snowflake
Fundamentals
Solid track record with excellent balance sheet and pays a dividend.
Similar Companies
Share Price & News
How has Shandong Weigao Group Medical Polymer's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
0%
OTCPK:SHWG.F
1.5%
US Medical Equipment
0.8%
US Market
1 Year Return
n/a
OTCPK:SHWG.F
9.7%
US Medical Equipment
1.9%
US Market
No trading data on SHWG.F.
No trading data on SHWG.F.
Share holder returns
| SHWG.F | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 1.5% | 0.8% |
| 30 Day | 0% | 0.7% | 3.4% |
| 90 Day | 8.0% | 2.4% | 2.1% |
| 1 Year | n/a | 10.6%9.7% | 4.2%1.9% |
| 3 Year | n/a | 70.2%65.0% | 46.7%37.2% |
| 5 Year | -5.0%-5.0% | 136.0%109.1% | 62.3%44.5% |
Price Volatility Vs. Market
How volatile is Shandong Weigao Group Medical Polymer's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
Should Shandong Weigao Group Medical Polymer Company Limited (OTCPK:SHWG.F) Be Part Of Your Portfolio?Valuation
Is Shandong Weigao Group Medical Polymer undervalued based on future cash flows and its price relative to the stock market?
19.39x
Price to Earnings (PE) ratio
Intrinsic Value Based on Future Cash Flows
Shandong Weigao Group Medical Polymer's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Shandong Weigao Group Medical Polymer's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Shandong Weigao Group Medical Polymer is good value based on earnings compared to the US Medical Equipment industry average.
Shandong Weigao Group Medical Polymer is overvalued based on earnings compared to the United States of America market.
Price Based on Expected Growth
Shandong Weigao Group Medical Polymer is poor value based on expected growth next year.
Price Based on Value of Assets
Shandong Weigao Group Medical Polymer is good value based on assets compared to the US Medical Equipment industry average.
Next Steps
Future Growth
How is Shandong Weigao Group Medical Polymer expected to perform in the next 1 to 3 years based on estimates from 9 analysts?
14.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Shandong Weigao Group Medical Polymer's revenue is expected to grow by 13.6% yearly, however this is not considered high growth (20% yearly).
Shandong Weigao Group Medical Polymer's earnings are expected to grow by 14.8% yearly, however this is not considered high growth (20% yearly).
Shandong Weigao Group Medical Polymer's revenue growth is expected to exceed the United States of America market average.
Shandong Weigao Group Medical Polymer's earnings growth is expected to exceed the United States of America market average.
Shandong Weigao Group Medical Polymer's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Earnings per Share Growth Estimates
Future Return on Equity
Shandong Weigao Group Medical Polymer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
Next Steps
Past Performance
How has Shandong Weigao Group Medical Polymer performed over the past 5 years?
15.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Shandong Weigao Group Medical Polymer's year on year earnings growth rate has been positive over the past 5 years.
Shandong Weigao Group Medical Polymer's 1-year earnings growth exceeds its 5-year average (40.1% vs 15.1%)
Shandong Weigao Group Medical Polymer's earnings growth has exceeded the US Medical Equipment industry average in the past year (40.1% vs 28.9%).
Return on Equity
Shandong Weigao Group Medical Polymer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
Return on Assets
Shandong Weigao Group Medical Polymer used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
Return on Capital Employed
Shandong Weigao Group Medical Polymer has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
Next Steps
Financial Health
How is Shandong Weigao Group Medical Polymer's financial position?
Financial Position Analysis
Shandong Weigao Group Medical Polymer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Shandong Weigao Group Medical Polymer's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Shandong Weigao Group Medical Polymer's level of debt (34.4%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has increased over the past 5 years (2.9% vs 34.4% today).
Debt is well covered by operating cash flow (42.6%, greater than 20% of total debt).
Interest payments on debt are well covered by earnings (EBIT is 28.1x coverage).
Balance Sheet
High level of physical assets or inventory.
Debt is covered by short term assets, assets are 2x debt.
Next Steps
Dividend
What is Shandong Weigao Group Medical Polymer's current dividend yield, its reliability and sustainability?
1.80%
Expected Dividend Yield
Dividend Yield and Payments Analysis
Shandong Weigao Group Medical Polymer's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.43%).
Shandong Weigao Group Medical Polymer's dividend is below the markets top 25% of dividend payers in United States of America (3.67%).
Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
Dividends per share have increased over the past 10 years.
Current Payout to Shareholders
Dividends paid are thoroughly covered by earnings (7.5x coverage).
Future Payout to Shareholders
Dividends after 3 years are expected to be well covered by earnings (3.6x coverage).
Next Steps
Management
What is the CEO of Shandong Weigao Group Medical Polymer's salary, the management and board of directors tenure and is there insider trading?
2.6yrs
Average management tenure
CEO
Jing Long (44yo)
1.1yrs
Tenure
CN¥2,325,000
Compensation
Mr. Long Jing has been Chief Executive Officer and Executive Director of Shandong Weigao Group Medical Polymer Company Limited since August 29, 2018. Mr. Jing serves as a Vice-General Manager of Shandong W ...
CEO Compensation Analysis
Jing's remuneration is lower than average for companies of similar size in United States of America.
Jing's compensation has been consistent with company performance over the past year, both up more than 20%.
Management Age and Tenure
2.6yrs
Average Tenure
47yo
Average Age
The tenure for the Shandong Weigao Group Medical Polymer management team is about average.
Board Age and Tenure
7.9yrs
Average Tenure
57yo
Average Age
The tenure for the Shandong Weigao Group Medical Polymer board of directors is about average.
Insider Trading
No 3 month open market individual insider trading information.
Ownership Breakdown
Management Team
Hua Wei Zhang (55yo)
Chairman & Compliance Officer
- Tenure: 3.5yrs
- Compensation: CN¥2.31m
Phillis Wong (50yo)
Company Secretary
- Tenure: 13.3yrs
Hong Feng Ju (44yo)
Vice-General Manager of the Production and Supply Chain
- Tenure: 0yrs
Jian Bo Gong (51yo)
Executive Director
- Tenure: 6.5yrs
- Compensation: CN¥10.89m
Jing Long (44yo)
CEO & Executive Director
- Tenure: 1.1yrs
- Compensation: CN¥2.33m
Xue Feng Wu (41yo)
Chief Financial Officer
- Tenure: 2.6yrs
Board Members
Shu Hua Zhou (62yo)
Non Executive Director
- Tenure: 18.8yrs
Hua Wei Zhang (55yo)
Chairman & Compliance Officer
- Tenure: 3.5yrs
- Compensation: CN¥2.31m
Yi Wang (59yo)
Executive Director
- Tenure: 18.8yrs
- Compensation: CN¥1.27m
Xiao Yun Chen (45yo)
Supervisor
- Tenure: 0yrs
Dong Mei Bi (55yo)
Chairman of the Board of Supervisors
- Tenure: 0yrs
Ming Zhong Fu (68yo)
Independent Non-Executive Director
- Tenure: 7.9yrs
- Compensation: CN¥108.00k
Jin Xia Wang (64yo)
Independent Non-Executive Director
- Tenure: 7.3yrs
- Compensation: CN¥108.00k
Wai Hung Lo (59yo)
Independent Non Executive Director
- Tenure: 10.1yrs
- Compensation: CN¥154.00k
Jian Bo Gong (51yo)
Executive Director
- Tenure: 6.5yrs
- Compensation: CN¥10.89m
Jing Long (44yo)
CEO & Executive Director
- Tenure: 1.1yrs
- Compensation: CN¥2.33m
Company Information
Shandong Weigao Group Medical Polymer Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Shandong Weigao Group Medical Polymer Company Limited
- Ticker: SHWG.F
- Exchange: OTCPK
- Founded: 2000
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: HK$37.490b
- Listing Market Cap: HK$4.793b
- Shares outstanding: 4.52b
- Website: https://www.weigaogroup.com
Number of Employees
Location
- Shandong Weigao Group Medical Polymer Company Limited
- Torch Hi-Tech Science Park
- 18 Xingshan Road
- Weihai
- Shandong Province
- 264210
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1066 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Feb 2004 |
| UK2 | DB (Deutsche Boerse AG) | Yes | Foreign Shares-Foreign Listed | DE | EUR | Feb 2004 |
| SHWG.F | OTCPK (Pink Sheets LLC) | Yes | Foreign Shares-Foreign Listed | US | USD | Feb 2004 |
| 1066 | SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Feb 2004 |
| 1066 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Foreign Shares-Foreign Listed | HK | HKD | Feb 2004 |
| SHWG.Y | OTCPK (Pink Sheets LLC) | ADS REP SHS H | US | USD | Nov 2010 |
Biography
Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People’s Republic of China. The company operates thr ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/18 00:21 |
| End of Day Share Price | 2019/07/29 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.